Hierarchical linear modeling Radiotherapy Background: Although patients with head and neck cancer are at increased risk for depressive symptoms compared with other cancer patients, few longitudinal studies have evaluated changes in and predictors of this symptom over time.
clinical evaluation. Several patient characteristics were associated with depressive symptoms. Implications for Practice: Knowledge on prevalence, time course, and predictors of depressive symptoms from this study can be used to identify patients at higher risk for more severe depressive symptoms. P atients with head and neck cancer (HNC) experience multiple, complex, and concurrent physical, functional, and psychosocial problems as a consequence of their disease and its treatment; the uncertainty of the diagnosis; as well as the impact of the disease on nutritional intake, ventilation, and communication. 1 These negative effects on vital functions, as well as facial disfigurement, may contribute to the high prevalence of depressive symptoms reported by these patients. In fact, depressive symptoms are more common in HNC patients than in other cancer patients, 2 with prevalence rates that range from 22% to 57%. 2 Findings from a systematic review 1 suggest that HNC patients report high levels of depressive symptoms from diagnosis to the first 6 months after treatment. In addition, depressive symptoms are reported by survivors of this cancer several years after treatment. 3 In most studies, the Hospital Anxiety and Depression Scale, the Beck Depression Inventory, or the Center for Epidemiologic StudiesYDepression (CES-D) scale were used to measure depressive symptoms. 1 However, many studies of psychological distress in HNC patients used general rather than specific measures of depressive symptoms or assessed depressive symptoms as 1 of many dimensions in a quality of life (QOL) measure. Furthermore, the majority of these studies were cross-sectional and evaluated HNC patients who received a variety of cancer treatments.
When reviewing the literature from the past 15 years, 12 longitudinal studies were found that evaluated depressive symptoms in HNC patients who underwent radiotherapy (RT) specifically, using the CES-D, 4 the Hospital Anxiety and Depression Scale, 5Y11 the Beck Depression Inventory, 10 ,12Y14 and the Self-rating Depression Scale. 15 In all of these studies, levels of depressive symptoms increased during RT, peaked at the completion of treatment, and then decreased over time. These studies varied in terms of length of follow-up, from assessments before and after treatment 6, 13 to a total of 3 years. 5 In addition, sample sizes across these studies ranged from 21 12 to 220. 5 Several predictors of depressive symptoms in patients with HNC were identified, including younger age, 5, 10 being single or living alone, 10, 16 less education, 15, 16 working, 10 smoking, 10, 16 alcohol use, 16 specific working conditions, 17 decreased social support, 17 higher stage of disease, 5 tumor site, 17 combined modality treatment, 5 aggressive RT regimens, 15 higher number of comorbidities, 1 lower physical functioning, 18 and increased numbers of physical symptoms and side effects. 7, 11, 12, 17 Findings regarding gender as a predictor of depressive symptoms are inconclusive. 1 In addition, depressive symptoms were associated with malnutrition 19 and changes in body image, 4 as well as with increased anxiety 1 and decrements in various dimensions of QOL. 3, 6, 9, 14, 16 However, none of the aforementioned studies evaluated the combination of demographic, clinical, symptom, and psychosocial characteristics as predictors of depressive symptoms in the same sample of HNC patients who underwent RT.
Based on findings from the review of depressive symptoms in HNC patients, 1 additional research is warranted to evaluate which demographic and clinical characteristics, as well as other symptoms and psychosocial characteristics, are associated with depressive symptoms across the trajectory of these patients' illness. Although a substantial body of literature on depressive symptoms in HNC patients exists, relatively small sample sizes limit one's ability to compare different subgroups and evaluate the effects of multiple predictors. In addition, differences in study designs, choice of measures, and characteristics of the patients evaluated limit one's ability to compare findings across studies.
Newer methods of longitudinal analysis, such as hierarchical linear modeling (HLM), allow for an evaluation of changes in depressive symptoms over time, as well as for the identification of characteristics that predict variability in initial levels (intercept) and trajectories (slope) of depressive symptoms. This type of analysis may provide insights into which patients experience higher levels of depressive symptoms. Therefore, the purposes of this longitudinal study, in a sample of patients with HNC, were to determine whether levels of depressive symptoms changed from the initiation of RT and for 6 months after and to determine whether specific demographic, clinical, symptom, or psychosocial characteristics were associated with initial levels of or changes in depressive symptoms. n Materials and Methods
Patients and Settings
This study is part of a larger, longitudinal study of symptoms and QOL in oncology patients. The patients with HNC were recruited in the RT unit at the Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital. Patients were eligible to participate if they were 18 years or older; were able to read, write, and understand Norwegian; and were scheduled to receive RT for HNC. Patients were excluded if they were to receive RT for brain metastases or had a disease that affected their cognitive ability. The study was approved by the Regional Committee for Medical and Health Research Ethics, the Norwegian Directorate of Health, the privacy ombudsman at the hospital, and the institutional review board at the Norwegian Radium Hospital.
Conceptual Framework
The Theory of Symptom Management (TSM) served as the conceptual framework for the original study. The TSM was first introduced by faculty members at the University of California, San Francisco, School of Nursing in 1994 20 and has undergone several revisions. 21 The TSM consists of 3 essential concepts: symptom experience, symptom management strategies, and symptom
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Study Procedures
During the first appointment in the RT unit, approximately 8 days before the initiation of RT, patients were provided with information about the study and invited to participate. After obtaining written, informed consent, patients completed selfreport questionnaires to obtain information on demographic and clinical characteristics, as well as several instruments that assessed symptoms and QOL. Patients completed mailed questionnaires at approximately 1, 2, 3, and 6 months after enrollment.
INSTRUMENTS
Demographic Characteristics. A demographic questionnaire obtained information on marital status, living situation, level of education, and employment status. Clinical Characteristics. Medical records were reviewed by study personnel for information on specific HNC diagnoses and previous treatments. Based on the patients' tumor, node, and metastases classification at the time of diagnosis, stage of disease was classified into 4 stages (I = T1N0M0, II = T2N0M0, III = T1-2N1M0 or T3N0-1M0, and IV = T4, N2-3, or M+) using the Union for International Cancer Control guidelines. 22 Karnofsky Performance Status (KPS) Scale. Physical functioning was evaluated by the patients using the KPS scale, 23, 24 where the score ranges from 0 (dead) to 100 (normal; no complaints; no evidence of disease) in 10-point increments. As patients in the current study were outpatients at the time of enrollment, the 40-to-100Ypoint range (40 = disabled; requires special care and assistance) of the KPS scale was used. The KPS scale has well-established validity and reliability with cancer patients. 25 Self-administered Comorbidity Questionnaire-19 (SCQ-19). Comorbidities were evaluated using the SCQ-19, 26 which includes 16 common and 3 optional conditions. Patients indicated whether they had the condition, and if yes, if they received treatment for it and if it limited their activities. The SCQ-19 has established validity and reliability with patients with chronic medical conditions when using the total score (0Y57). 26 In this study, the total number of comorbidities (0Y19) was used in the analyses.
CES-D Scale. Depressive symptoms were evaluated using the CES-D, 27 which consists of 20 items selected to represent the major symptoms in the clinical syndrome of depression. Patients rated how often they experienced symptoms over the past week. The score for each item ranges from 0 to 3, and the total score ranges from 0 to 60. A total CES-D score of 16 or higher indicates the need for clinical evaluation of depressive symptoms. Although the CES-D was developed for use in the general population, it has been used extensively and has established validity and reliability in patients with cancer in general 28 and in HNC patients. 29 In this study, Cronbach's ! for the CES-D was .87.
Based on previous literature, 7, 11, 12, 17 3 symptoms (ie, sleep disturbance, fatigue, pain) were evaluated as predictors of initial levels and trajectories of depressive symptoms.
General Sleep Disturbance Scale (GSDS). Sleep disturbance was evaluated using the GSDS, 30 which consists of 21 items that assess various aspects of sleep disturbance in the past week. The frequency of each item is rated on a 0 (never) to 7 (everyday) numeric rating scale (NRS). The total GSDS score is the sum of the 21 items that can range from 0 (no sleep disturbance) to 147 (extreme sleep disturbance). A total score of 43 or higher indicates high levels of sleep disturbance. 30 The GSDS has established validity and reliability with employed women 30 and has been used with cancer patients who underwent RT. 31 In this study, Cronbach's ! for the GSDS was .86.
Lee Fatigue Scale (LFS). Fatigue and energy levels were evaluated using the LFS, 32 which consists of 18 items, divided in 2 subscales (ie, fatigue and energy). Patients were asked to rate each item based on how they feel ''right now'' on a 0-to-10 NRS. The subscale scores are calculated as the mean of the subscales items, ranging from 0 to 10, with higher scores indicating higher levels of fatigue or energy. A score of 4.4 or higher indicates high levels of fatigue and a score of 4.8 or lower indicates low levels of energy. 31 The LFS has well-established validity and reliability in cancer patients. 33 In this study, Cronbach's ! values for the fatigue and energy subscales were .95 and .91, respectively.
Brief Pain Inventory (BPI). Pain was evaluated using a single item from the BPI, 34 where patients reported whether or not they had pain. The 15 item BPI has been used extensively and has well-established validity and reliability in cancer patients. 35, 36 Multidimensional Quality of Life ScaleYCancer (MQOLS-CA). The MQOLS-CA 37 measures different dimensions of QOL (ie, psychological well-being, physical well-being, nutrition, symptom distress, interpersonal well-being) and has well-established validity and reliability. 37Y39 Selected subscales and a single item from the MQOLS-CA were used to assess nutrition, social support, and satisfaction with looks, which were associated with depressive symptoms in previous studies of patients with HNC. 4, 17, 19 MQOLS-CA Nutrition. Nutrition was evaluated using the subscale from the MQOLS-CA. 37 The Nutrition subscale consists of 4 items that assess appetite, food intake, taste, and weight concerns. Each item is rated on a 0-to-10 NRS. A subscale score was calculated as the mean of the 4 items, where higher scores indicate better nutritional status. In this study, Cronbach's ! for the Nutrition subscale was .73.
MQOLS-CA Interpersonal Well-Being. Social support and social role/functioning, shortened to social support, was evaluated using the subscale from the MQOLS-CA. 37 The subscale consists of 5 items that measure these 2 constructs, and each item is rated on a 0-to-10 NRS. A subscale score was calculated as the mean of the 5 items, where higher scores indicate better social support. In this study, Cronbach's ! for the Interpersonal Well-Being subscale was .65, possibly because of the 2 different constructs in this subscale.
MQOLS-CA Satisfaction With Looks. Satisfaction with looks was evaluated using a single item from the MQOLS-CA. 37 Patients were asked to rate to what degree they were satisfied with their looks on a 0 (very dissatisfied) to 10 (very satisfied) NRS.
Data Analysis
Descriptive statistics and frequency distributions for the sample characteristics and symptom severity scores at enrollment were calculated using SPSS version 20 (SPSS Inc, Chicago, Illinois). A mean CES-D score was calculated for each of the 5 assessments, for use in the subsequent statistical analyses.
Hierarchical linear modeling, based on full maximum likelihood estimation, was performed using the software developed by Raudenbush and colleagues. 40, 41 Compared with other methods for analyzing change, HLM has 2 major advantages. First, it can accommodate unbalanced designs and uses all available data by applying the missing at random assumption, which allows for analysis of data where the number and spacing of assessments vary across respondents. Second, HLM has the ability to model individual change, which helps to identify more complex patterns of change that often are overlooked by other methods.
With HLM, repeated measures of the outcome variable (ie, depressive symptoms) are conceptualized as being nested within individuals and the analysis of change in depressive symptom scores is at 2 levels: within persons (level 1) and between persons (level 2). At level 1, the outcome is conceptualized as varying within individuals and is a function of person-specific change parameters plus error. At level 2, the person-specific change parameters are multivariate outcomes that vary across individuals. Level 2 outcomes can be modeled as a function of demographic, clinical, symptom, or psychosocial characteristics that vary between individuals, plus an error associated with the individual. Combining level 1 with level 2 results in a mixed model with fixed and random effects. 40 During the level 1 analysis, intraindividual variability in ratings of depressive symptoms over time was examined. Four level 1 models were compared to determine whether the patients' depressive symptoms did not change over time (ie, no time effect), changed at a constant rate either accelerating or decelerating (ie, linear time effect, no bends), changed at a rate that accelerated and decelerated over time (ie, quadratic effect, 1 bend), or changed at a rate that accelerated, decelerated, and accelerated over time (ie, cubic effect, 2 bends). At this point, the level 2 model was constrained to be unconditional (ie, no predictors) and likelihood ratio tests (ie, comparison of the deviance values among the models) were used to determine the best model.
During the level 2 analysis, interindividual differences in the trajectories of depressive symptoms were examined by modeling the individual change parameters (ie, intercept and slope) as a function of proposed predictors. The first column in Table 1 presents the proposed predictors that were used in the level 2 analysis. This list is based on a review of the literature on depressive symptoms in patients with HNC. 1,5,7,10Y12,15Y19 To improve estimation efficiency and construct a parsimonious model, exploratory analyses were done in which each potential predictor was assessed to determine whether it would result in a better fitting model if it alone was added as a level 2 predictor. Predictors with a t value of less than 2, which indicates a lack of significant effect, were dropped from subsequent model testing.
All significant predictors from the exploratory analyses, indicated with an ''Â'' in Table 1 , were entered into the model to predict each individual change parameter. Only predictors that maintained a statistically significant contribution in conjunction with other predictors were retained in the final model. A P value of G.05 indicates statistical significance. The effects of each of these predictors are illustrated in the figures as adjusted change curves for depressive symptoms that were estimated based on differences in dichotomous outcome predictors (yes/no) or continuous outcome predictors (higher/lower score calculated based on 1 SD above and below the mean score of the predictor).
n Results
Patient Characteristics
A total of 207 patients were approached and 79% (n = 163) consented to participate. Those patients who declined to participate were significantly older (mean, 66 years) than those who agreed (mean, 61 years; P = .011). Although reasons for refusal to participate were not recorded systematically, lack of energy was the most common reason offered by some patients. Five patients were excluded after enrollment because of a non-HNC diagnosis or an altered treatment plan. Of the remaining 158 patients, 84% (n = 133) completed the questionnaires before initiation of RT. No differences in demographic or clinical characteristics were found between patients who did and did not complete these questionnaires. The overall attrition rate for this study was 37%. Of the 133 patients who completed the enrollment questionnaire, 59% completed all 5 assessments. Among those who did not complete all of the assessments, a higher percentage of patients had a primary level of education compared with secondary (P = .009) and received palliative RT (P = .018). A significant difference in mean (SD) CES-D scores at enrollment was found between patients who did (10.8 [7.8] ) and patients who did not (14.7 [10.9]; t = 2.261, P = .026) complete the study.
The patients' demographic, clinical, and treatment characteristics are presented in Table 2 . Most of the patients were married or partnered and had at least a secondary level of education, and their mean age was 60 years. The most common comorbid conditions assessed on the SCQ-19 were neck/back pain (35%) and hypertension (29%), and 13% of patients indicated that they had a comorbid depression. Most patients received a total RT dose of 70 Gray over a period of 6 weeks.
Individual and Mean Change in Depressive Symptoms
The goodness-of-fit tests of the deviance among the models in the first level of the HLM analysis indicated that a cubic model fit the data best (P G .001). Table 3 presents the estimates for the unconditional cubic change model. The cubic trajectory of depressive symptoms, illustrated in Figure 1A , changed from 12.6 before RT to just below 16 during and at the completion of RT, followed by a decrease to about the same score of 12.6 at 6 months. Figure 1B illustrates the individual trajectories for depressive symptoms, which indicates a large amount of interindividual variability in depressive symptom scores. The mean scores depicted in the figures are estimated or predicted means based on the HLM analyses. Figure 2 displays the percentage of patients with CES-D scores above the cutoff of 16 or higher, indicating clinically meaningful levels of depressive symptoms, as well as the observed mean scores at each assessment. A cross-tabulation analysis indicated that among those who completed both the enrollment and the 6-month assessments, 55% of patients who reported CES-D scores 16 or higher at enrollment still had elevated scores at 6 months.
Interindividual Differences in Levels of Depressive Symptoms
As shown in the final model in Table 3 , the 5 characteristics that predicted interindividual differences in depressive symptoms at enrollment (ie, intercept) were the occurrence of HNC surgery in the 6 weeks before RT, sleep disturbance, fatigue, social support, and satisfaction with looks.
To illustrate the effects of these predictors on patients' initial levels of depressive symptoms, Figure 3 (AYE) displays the ad-justed change curves for depressive symptoms that were estimated based on differences in the occurrence of HNC surgery in the 6 weeks before RT (yes/no; Figure 3A ), sleep disturbance (higher/lower levels calculated based on T1 SD of the mean GSDS total score; Figure 3B ), fatigue (higher/lower levels calculated based on T1 SD of the mean LFS fatigue subscale score; Figure 3C ), social support (higher/lower levels calculated based on T1 SD of the mean MQOLS-CA Interpersonal Well-Being subscale score; Figure 3D ), and satisfaction with looks (higher/ lower levels calculated based on T1 SD of the mean MQOLS-CA item score; Figure 3E ). None of the characteristics identified in the exploratory analyses (ie, marital status, number of comorbidities, fatigue, energy, nutrition, depressive symptoms at enrollment) predicted interindividual differences in any of the slope parameters (ie, trajectories) for depressive symptoms.
n Discussion Consistent with previous reports on depressive symptoms in patients with HNC who underwent RT, 4Y15 severity of depressive symptoms increased during RT, peaked around completion, and then decreased to pretreatment levels in this sample. However, the use of HLM, compared with more traditional statistical approaches (eg, repeated-measures analysis of variance), provided evidence of a large amount of interindividual variability in levels of depressive symptoms.
Both before RT and 6 months after enrollment, the mean CES-D score for this Norwegian sample of HNC patients was 12.6. This score is similar to CES-D scores reported in a Dutch longitudinal study of depressive symptoms in HNC patients receiving surgery and/or RT, 42 where a moderate decrease in mean CES-D scores from 12.2 before treatment to 10.2 at 6 months was found. However, they did not assess depressive symptoms during treatment. In the current study, the severity of depressive symptoms peaked during treatment. At 1 month, patients mean CES-D scores were just below the clinically meaningful cutoff score of 16 or higher. On the basis of a previous study of breast cancer patients, 43 patients with scores just below this cutoff may be experiencing subsyndromal levels of depressive symptoms that warrant clinical evaluation. These subthreshold levels of depressive symptoms may be clinically important because subsyndromal depression was associated with decreased QOL, 44 as well as an increased risk for clinical depression, 45 in the general population.
Although mean CES-D scores were below the clinically meaningful cutoff score throughout our study, a large amount of interindividual variability was identified ( Figure 1B) . Furthermore, at each assessment, between 29% and 42% of the patients reported CES-D scores of 16 or higher (Figure 2 ). This percentage is higher than that reported in the Dutch study, where the percentage of patients with CES-D scores of 16 or higher was 28% before treatment and 24% at 6 months. 42 When compared with other cancer diagnoses, the occurrence rates in our patients are higher than that of patients newly diagnosed with prostate cancer (10%) 46 and gynecological cancer (23%) 47 but lower than those of patients newly diagnosed with breast cancer 47 and lung cancer (56%). 48 In addition, the occurrence rates are higher than those reported in a study of middle-aged and older people in the general population in Norway, where 21% of the responders had CES-D scores above the cutoff. 49 Given the significant difference in depressive symptom scores at enrollment between patients who did and did not complete the study, there is reason to believe that the levels of depressive symptoms during the study may be underestimated. In the current study, 13% of patients indicated on the SCQ-19 that they had a comorbid depression. Among these patients, only 18% reported that they received treatment for their depression. Although studies based on self-report assessments frequently report higher occurrence rates for depressive symptoms compared with structured clinical interviews, 50 there is reason to believe that a high percentage of our patients would benefit from evaluation of clinical depression and subsequent treatment.
Although previous studies of patients with HNC found that age, 10 marital status, 10 education level, 15 and employment status 10 were associated with depressive symptoms, the current study, as well as several other studies, 5, 7, 10, 15 was not able to find associations between depressive symptoms and demographic characteristics. These inconsistent findings suggest that demographic characteristics are not strong predictors of depressive symptoms in these patients. It should be noted that in the current study, a relatively high percentage of the sample was married, had at least a secondary level of education, and was not working, all of which are associated with lower levels of depressive symptoms. In addition, employment status may influence depressive symptoms to a lesser degree in a Norwegian sample because all cancer patients are eligible to receive some form of sick leave benefits.
Findings on the associations between depressive symptoms and clinical characteristics were not consistent in previous studies. Whereas some studies found that stage of disease, 5 tumor site, 17 and concurrent chemotherapy 5 were associated with depressive symptoms, others did not find associations. 10, 11, 15 The finding that patients who had surgery reported lower CES-D scores than did those who did not ( Figure 3A) is in contrast with 1 study with opposite results 5 and with another study that found no such association. 10 However, in both of these previous studies, fewer patients underwent surgery, compared with the current study. In addition, in the study by Joseph and colleagues, 5 the tumor site and stage of disease differed from those in the current study, which may have influenced the results. In the current study, patients who underwent surgery may have reported lower depressive symptom scores because they had started treatment and were less concerned about the outcome of their treatment. An alternative explanation is that patients who received surgery were under the impression that surgery was a more radical approach to treatment compared with primary RT and were more confident about the efficacy of their treatment.
Sleep disturbance ( Figure 3B ), fatigue ( Figure 3C ), social support ( Figure 3D ), and satisfaction with looks ( Figure 3E ) had an impact on initial levels of depressive symptoms. In the current study, higher levels of sleep disturbance and fatigue were associated with higher levels of depressive symptoms. Although sleep disturbance and fatigue were not reported as predictors of depressive symptoms in previous studies of patients with HNC who underwent RT, our findings are consistent with previous studies that evaluated associations between depressive symptoms and physical symptoms or side effects. 7, 11, 12 In addition, sleep disturbance and fatigue are both symptoms associated with clinical depression. 1 The fact that patients in the current study reported GSDS scores above the cutoff score of 43 or higher and LFS fatigue scores below the cutoff score of 4.4 or higher is interesting. The reason for the co-occurrence of a relatively high level of sleep disturbance and a relatively low level of fatigue may be the timing of the assessment (ie, prior to the initiation of RT). Fatigue generally occurs during RT and increases over time. 51 In contrast, patients may experience sleep disturbance from a variety of causes (eg, pain, worry, stress).
Consistent with previous studies 17, 42 patients with higher levels of social support reported lower levels of depressive symptoms before RT. One study 17 argued that patients with HNC were more likely to come from less privileged social classes because of the risk factors associated with HNC (eg, smoking, alcohol), which may result in less social support.
The final predictor of initial levels of depressive symptoms in the current study was satisfaction with looks. A recent study among HNC patients who underwent RT 4 found an association between depressive symptoms and body image during and after completion of, but not before, RT. Patients with HNC experience a significant amount of disfigurement and dysfunction associated with treatment. 4 It is plausible that these changes in body image lead to decreased satisfaction with looks and interference with self-esteem that is associated with higher levels of depressive symptoms. A few limitations need to be addressed. First, depressive symptoms were evaluated using a self-report questionnaire, while a structured clinical interview is the gold standard. However, selfreport measures are resource-efficient in research and seem to be the best approach for identifying individuals who may be at increased risk and who may potentially benefit from an intervention. 50 Second, the sample size was relatively small and the overall attrition rate was 37% for this study. Although detailed reasons for withdrawal were not obtained, it is reasonable to hypothesize that HNC disease and its treatment resulted in severe symptoms in some patients and decreased their motivation to continue study participation. In addition, the questionnaire was extensive and the follow-up period was relatively long. Finally, the questionnaires were distributed by mail, which may have influenced the response rate.
The lack of significant predictors of the trajectory of depressive symptoms may be partially explained by the sample size because support for predictors of a cubic rate of change in an outcome may require a larger sample and greater variability in the assessed characteristics. 52 In addition, as this study was part of a larger study of oncology patients, an exhaustive list of potential predictors reported in previous studies of patients with HNC (eg, smoking, alcohol intake) was not evaluated. It should be noted that the inclusion of patients with different treatment intents, tumor sites, and stages of disease results in a more heterogeneous sample. However, as noted in a previous study, 15 most publications on depressive symptoms in patients with HNC did not differentiate among HNC diagnoses. Finally, most of the patients were white and married and had a secondary level of education or higher, which limits the generalizability of the study findings.
Clinicians can use the knowledge from the current study on prevalence, time course, and predictors of depressive symptoms to identify higher-risk patients and educate patients about this symptom. In addition, clinicians may choose to refer patients with higher levels of depressive symptoms for psychological consultation or initiate treatment with antidepressants. Considering the relatively large proportion of patients who reported clinically meaningful levels of depressive symptoms, future studies that test the efficacy of interventions targeted at reducing depressive symptoms are needed. In addition, interventions targeted to mitigate the modifiable risk factors identified in this study (eg, sleep disturbance, fatigue, social support) need to be tested, as this approach may lessen depressive symptoms.
